Health Care

Intuitive Surgical Stock Climbs After Company Tops Q4 Earnings
Intuitive Surgical Stock Climbs After Company Tops Q4 Earnings
FDA Approves Guardant Health's Blood Test To Guide Treatment For Advanced Colorectal Cancer
FDA Approves Guardant Health's Blood Test To Guide Treatment For Advanced Colorectal Cancer
Hoth Therapeutics Early Cancer Trial Succeeds With 100% Patient Response, Cuts Disease Severity By Half
Hoth Therapeutics Early Cancer Trial Succeeds With 100% Patient Response, Cuts Disease Severity By Half
FDA Approves Guardant Health's Blood Test To Guide Treatment For Advanced Colorectal Cancer
FDA Approves Guardant Health's Blood Test To Guide Treatment For Advanced Colorectal Cancer
Hoth Therapeutics Early Cancer Trial Succeeds With 100% Patient Response, Cuts Disease Severity By Half
Hoth Therapeutics Early Cancer Trial Succeeds With 100% Patient Response, Cuts Disease Severity By Half
Axogen Prices Upsized $124 Million Stock Offering
Axogen Prices Upsized $124 Million Stock Offering
Abbott Labs Stock Hits 52-Week Low As Outlook Disappoints
Abbott Labs Stock Hits 52-Week Low As Outlook Disappoints

Health Care Recent News

Janux Therapeutics Strikes Bristol Myers Biotech Deal Worth $800 Million
Janux Therapeutics Strikes Bristol Myers Biotech Deal Worth $800 Million
Janux Therapeutics signs a global licensing deal with Bristol Myers Squibb worth up to $800 million.
Corcept Therapeutics Experimental Lead Drug Cuts Death Risk By 35% In Advanced Ovarian Cancer Patients, Stock Jumps
Corcept Therapeutics Experimental Lead Drug Cuts Death Risk By 35% In Advanced Ovarian Cancer Patients, Stock Jumps
Corcept stock rises after a Phase 3 ovarian cancer trial showed longer survival and lower death risk, even as relacorilant faces an FDA setback in another use.
Ocugen (OCGN) Stock Tumbles After $22.5 Million Share Offering
Ocugen (OCGN) Stock Tumbles After $22.5 Million Share Offering
Ocugen shares sank sharply Wednesday after the biotech company announces a $22.5 million underwritten offering of common stock.
Boston Scientific Advises Removal Of Certain AXIOS Stents After Deployment Issues Surface
Boston Scientific Advises Removal Of Certain AXIOS Stents After Deployment Issues Surface
FDA is reviewing AXIOS stent delivery issues after Boston Scientific reported injuries and deaths, urging facilities to stop use and remove affected devices.
Johnson & Johnson Talc Plaintiffs Clear Key Expert Testimony Hurdle
Johnson & Johnson Talc Plaintiffs Clear Key Expert Testimony Hurdle
Thousands of women suing J&J over claims that its talc-based baby powder caused ovarian cancer cleared a key hurdle.
FDA Green Lights Avalon GloboCare's KetoAir Breathalyzer
FDA Green Lights Avalon GloboCare's KetoAir Breathalyzer
Avalon GloboCare stock traded lower despite renewing FDA registration for its KetoAir breath device, with marketing plans set for 2026.
Johnson & Johnson Expects 2026 Sales To Hit Almost $100 Billion
Johnson & Johnson Expects 2026 Sales To Hit Almost $100 Billion
Johnson & Johnson beat Q4 earnings and sales estimates, driven by strong cancer and MedTech growth, and issued a higher 2026 outlook as shares hovered near a 52-week high.
Big-Pharma Partner Harbour BioMed Boosts Stake In Spruce Biosciences
Big-Pharma Partner Harbour BioMed Boosts Stake In Spruce Biosciences
Harbour BioMed exercises its warrant to buy Spruce Biosciences shares, raising its stake to about 3.8% as the companies work together on the SPR202 drug program.
What Sparked Anteris Technologies (AVR) Stock Surge Over 52% After-Hours?
What Sparked Anteris Technologies (AVR) Stock Surge Over 52% After-Hours?
Anteris Technologies shares surged over 52% in after-hours trading following the announcement of a $200 million public offering and a strategic investment from Medtronic.
Moderna–Merck Cancer Vaccine Shows Durable Benefit At 5 Years In High-Risk Melanoma
Moderna–Merck Cancer Vaccine Shows Durable Benefit At 5 Years In High-Risk Melanoma
Moderna and Merck shared five-year study data showing their combined cancer treatment cut the risk of melanoma coming back or causing death by nearly half compared with Keytruda alone.
Connect With Us
instagramlinkedinyoutubeblueskymastodon
About Benzinga
Market Resources
Trading Tools & Education
Ring the Bell
© 2026 Benzinga | All Rights Reserved